Eupraxia Pharmaceuticals (EPRX) Receivables - Other (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Receivables - Other for 5 consecutive years, with $663235.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 178.05% year-over-year to $663235.0; the TTM figure through Mar 2026 stood at $663235.0 (up 178.05% YoY), while the FY2025 annual figure was $674226.0, up 194.59% from the prior year.
• Receivables - Other retreated to $663235.0 in Q1 2026 per EPRX's latest filing, from $674226.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $674226.0 in Q4 2025 and bottomed at $89715.0 in Q4 2022.
• Historically, Receivables - Other has averaged $253464.5 across 5 years, with a median of $167243.0 in 2024.
• On a YoY basis, Receivables - Other climbed as much as 194.59% in 2025 and fell as far as 13.29% in 2025.
• Eupraxia Pharmaceuticals' Receivables - Other stood at $89715.0 in 2022, then jumped by 112.46% to $190612.0 in 2023, then rose by 20.07% to $228872.0 in 2024, then soared by 194.59% to $674226.0 in 2025, then declined by 1.63% to $663235.0 in 2026.
• Business Quant data shows EPRX's Receivables - Other at $663235.0 in Q1 2026, $674226.0 in Q4 2025, and $139904.0 in Q3 2025.